<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02845882</url>
  </required_header>
  <id_info>
    <org_study_id>CCCG-LBL-2016</org_study_id>
    <nct_id>NCT02845882</nct_id>
  </id_info>
  <brief_title>LBL-2016 for Children or Adolescents in China</brief_title>
  <official_title>Modified BFM (Berlin-Frankfurt-Munster)Backbone Therapy for Chinese Children or Adolescents With Newly Diagnosed Lymphoblastic Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Cancer Group, China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shanghai Children's Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science &amp; Technology, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>West China Second University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Qilu Hospital of Shandong University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tianjin Medical University Cancer Institute and Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children’s Hospital of Sochow University, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nanjing Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xiangya Hospital of Central South University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Cancer Group, China</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The outcomes of children with lymphoblastic lymphoma (LBL) in China in the investigators'
      previous study were not unexpected. In this study, through further modification treatment
      protocols and strengthen domestic multicenter collaboration, the investigators try to improve
      survival for children with LBL when compared to the previous study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The treatment for LBL is an ALL (acute lymphoblastic leukemia)-based treatment. Additional,
      high dose L-asparaginase was reported to improve disease-free survival for patients with ALL.
      The event free survival (EFS) for pediatric LBL in most western countries have achieved 75%
      to 85%. However, the outcomes of children with LBL in China were not unexpected. In the
      previous study (CCCG-LBL-2010, 2009-2013), 96 patients with newly diagnosed LBL from 7
      Chinese pediatric oncology centers were included. At a median follow-up of 21 months (range,
      0.3~60.7months), the 2-year event free survival was 68±5% in all patients. Patients who had
      achieved complete remission on day 33 of induction had significantly better EFS than those
      who had not (77±6% v.s.17±10%, p&lt;0.005). In the current trial, the investigators try to
      improve survival for children with LBL in China through further modification treatment
      protocols and strengthen domestic multicenter collaboration.

      The BFM backbone will be used as the standard backbone therapy for this study. Three doses of
      daunorubicin are prescribed in induction compared with 4 doses in BFM studies. Cranial
      radiotherapy only saved for patients (&gt;2 yrs) with CNS disease at presentation.

      Complete remission (CR) is defined as at least 75% tumor regression, less than 5% BM (bone
      marrow)blasts, no CNS (central nervous system) disease, and disappearances of all evidence of
      disease from all sites for at least 4 weeks. Partial response (PR) is defined as &gt; 50% tumor
      regression, and no new lesions.Response to treatment is evaluated on day 33 and day 64 of
      induction.Patients will be stratified into 3 risk groups.

      Low risk group: patients (stage I or II) receive induction protocol I followed by the
      extracompartmental protocol M, and maintenance for up to a total therapy duration of 96
      weeks. Totally, 3 doses of PEG-asparaginase (Pegylated-asparaginase) are applied in this
      group.

      Intermediate risk group: patients (stage III or IV or receiving steroids within one week
      prior to the diagnosis) receive induction protocol I followed by the extracompartmental
      protocol M, reintensification protocol II, and maintenance for up to a total therapy duration
      of 104 weeks.Totally, 5 doses of PEG-asparaginase are applied in this group.

      High risk group:patients (failure to qualify a PR, or &gt;5% BM blasts, or with CNS disease on
      d33 of induction) receive induction protocol I followed by 6 intensive polychemotherapy
      blocks (R'), reintensification protocol II, and maintenance for up to a total therapy
      duration of 104 weeks. Totally, 11 doses of PEG-asparaginase are applied in this group.

      Second look biopsy/resection is indicated for patients without CR on day 64 of induction.
      Allo- or auto-hematopoietic stem-cell transplantation is recommended for patients with
      residual tumor. Patients who have disease progression at any time will be removed from this
      protocol therapy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event free survival for the whole cohort</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Event free survival for patients in High risk group</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival for all patients</measure>
    <time_frame>5 year</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Lymphoblastic Lymphoma</condition>
  <arm_group>
    <arm_group_label>Low risk group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Stage I or II: Induction I followed by extracompartmental Protocol M, and maintenance therapy for up to a total therapy duration of 96 weeks. Twenty triple intrathecal injections.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intermediate risk group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Stage III or IV or receiving steroids within one week prior to the diagnosis: Induction protocol I followed by the extracompartmental protocol M, reintensification protocol II, and maintenance therapy for up to a total therapy duration of 104 weeks. Twenty-two triple intrathecal injections.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High risk group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Failure to qualify a PR, or &gt;5% BM blasts, or with CNS disease on d33 of induction: Induction protocol I followed by 6 intensive polychemotherapy blocks (HR1'-HR2'-HR3'-HR1'-HR2'-HR3'), reintensification protocol II, and maintenance therapy for up to a total therapy duration of 104 weeks. Twenty-two triple intrathecal injections.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone,Vincristine, Pegylated-asparaginase, Cytarabine, Cyclophosphamide, Daunorubicin, 6-mercaptopurine</intervention_name>
    <description>Prednisone 60 mg/m2 per day,d1-28, then taper over 9 days; Vincristine 1.5 mg/m2 per day (max 2 mg),d1,8, 15, 22; Daunorubicin 30 mg/m2 per dose,d5,12,19; Pegylated-asparaginase 2000 IU/m2 per dose,d16,36,57; Cyclophosphamide 1000 mg/m2 per dose, d36, 57; Cytarabine 75 mg/m2 /d, d36-42,d 57-63; 6-Mercaptopurine 60 mg/m2 per day, d36-42, 57-63; Triple it, d8,29,36,57 1,8, 15, 22</description>
    <arm_group_label>Low risk group</arm_group_label>
    <arm_group_label>Intermediate risk group</arm_group_label>
    <arm_group_label>High risk group</arm_group_label>
    <other_name>Induction I</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>6-mercaptopurine,Methotrexate</intervention_name>
    <description>6-Mercaptopurine 25 mg/m2 per day, d1-56; Methotrexate 5g/m2 per dose, d1, 15, 29, 43; Triple it, d1, 15, 29, 43;</description>
    <arm_group_label>Low risk group</arm_group_label>
    <arm_group_label>Intermediate risk group</arm_group_label>
    <other_name>Protocol M</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone,Vincristine, Pegylated-asparaginase, Cytarabine, Cyclophosphamide, Doxorubicin, 6-mercaptopurine</intervention_name>
    <description>Dexamethasone 10 mg/m2 per day, d1-7, d15-21; Vincristine 1.5 mg/m2 per day (max 2 mg), d1, 8, 15; Doxorubicin 30 mg/m2 per dose, d1, 8, 15; Pegylated-asparaginase 2,000 IU/m2 per dose, d3, 24; Cyclophosphamide 1000 mg/m2 per dose, d29; Cytarabine 75 mg/m2 /d, d29-35; 6-Mercaptopurine 60 mg/m2 per day, d29-35; Triple it, d1, 29;</description>
    <arm_group_label>Intermediate risk group</arm_group_label>
    <arm_group_label>High risk group</arm_group_label>
    <other_name>Reinduction II</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone,Vincristine, Pegylated-asparaginase, Cytarabine, Cyclophosphamide, Methotrexate</intervention_name>
    <description>Dexamethasone 20mg/m2/day, d1-5; Vincristine 1.5 mg/m2 per day (max 2 mg), d1, 6; Methotrexate 5000mg/m2, d1; Cyclophosphamide 200mg/m2/dose, q12h×5, d2-4; Cytarabine 2000mg/m2/dose, ，q12h×2, d5; Pegylated-asparaginase 2,000 IU/m2 per dose, d6; Triple it, d1;</description>
    <arm_group_label>High risk group</arm_group_label>
    <other_name>HR 1'</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone, Vindesine, Methotrexate, Ifosfamide, Daunorubicin, Pegylated-asparaginase</intervention_name>
    <description>Dexamethasone 20mg/m2/day, d1-5; Vindesine 3mg/m2（MAX 5mg）, d1, 6; Methotrexate 5000mg/m2, d1; Ifosfamide 800mg/m2/dose, q12h×5,d2-4; Daunorubicin 25mg/m2/dose, d5; Pegylated-asparaginase 2,000 IU/m2 per dose, d6; Triple it, d1;</description>
    <arm_group_label>High risk group</arm_group_label>
    <other_name>HR 2'</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone, Cytarabine, Etoposide, Pegylated-asparaginase</intervention_name>
    <description>Dexamethasone 20mg/m2/day, d1-5; Cytarabine 2000mg/m2/dose，q12h× 4, d1, 2; Etoposide 100mg/m2/dose，q12h×5, d3,4,5; Pegylated-asparaginase 2,000 IU/m2 per dose, d6; Triple it, d5;</description>
    <arm_group_label>High risk group</arm_group_label>
    <other_name>HR 3'</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate, 6-mercaptopurine</intervention_name>
    <description>6-mercaptopurine 50 mg/m2 per day, Daily; Methotrexate 20 mg/m2 per dose, Once a week; Triple it, Once every 4 weeks for 12 times;</description>
    <arm_group_label>Low risk group</arm_group_label>
    <arm_group_label>Intermediate risk group</arm_group_label>
    <arm_group_label>High risk group</arm_group_label>
    <other_name>maintenance therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have newly diagnosed lymphoblastic lymphoma; Patients shall have had no
             prior cytotoxic chemotherapy with the exception of steroids (&lt;420mg/m2)

        Exclusion Criteria:

          -  Patients with Down syndrome;

          -  Morphologically unclassifiable lymphoma

          -  Patients with congenital immunodeficiency, chromosomal breakage syndrome, prior organ
             transplantation, previous malignancy of any type, or known positive HIV serology.

          -  Evidence of pregnancy or lactation period.

          -  Ph+ lymphoblastic lymphoma
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Months</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yi-Jin Gao, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Children's Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yi-Jin Gao, M.D.</last_name>
    <phone>86-21-38626161</phone>
    <phone_ext>82064</phone_ext>
    <email>gaoyijin@scmc.com.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jing-Yan Tang, M.D.</last_name>
    <email>tangjingyan@scmc.com.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>West China Second University Hospital</name>
      <address>
        <city>Chengdu</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xia Guo, M.D.</last_name>
      <email>guoxkl@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai Children's Medical Center</name>
      <address>
        <city>Shanghai</city>
        <zip>200127</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yi-Jin Gao, M.D.</last_name>
      <phone>86-21-38626161</phone>
      <phone_ext>82064</phone_ext>
      <email>gaoyijin@scmc.com.cn</email>
    </contact>
    <contact_backup>
      <last_name>Jing-yan Gao, M.D.</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Burkhardt B, Reiter A, Landmann E, Lang P, Lassay L, Dickerhoff R, Lakomek M, Henze G, von Stackelberg A. Poor outcome for children and adolescents with progressive disease or relapse of lymphoblastic lymphoma: a report from the berlin-frankfurt-muenster group. J Clin Oncol. 2009 Jul 10;27(20):3363-9. doi: 10.1200/JCO.2008.19.3367. Epub 2009 May 11.</citation>
    <PMID>19433688</PMID>
  </results_reference>
  <results_reference>
    <citation>Reiter A, Schrappe M, Ludwig WD, Tiemann M, Parwaresch R, Zimmermann M, Schirg E, Henze G, Schellong G, Gadner H, Riehm H. Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: a BFM group report. Blood. 2000 Jan 15;95(2):416-21.</citation>
    <PMID>10627444</PMID>
  </results_reference>
  <results_reference>
    <citation>Moghrabi A, Levy DE, Asselin B, Barr R, Clavell L, Hurwitz C, Samson Y, Schorin M, Dalton VK, Lipshultz SE, Neuberg DS, Gelber RD, Cohen HJ, Sallan SE, Silverman LB. Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. Blood. 2007 Feb 1;109(3):896-904. Epub 2006 Sep 26.</citation>
    <PMID>17003366</PMID>
  </results_reference>
  <results_reference>
    <citation>Stary J, Zimmermann M, Campbell M, Castillo L, Dibar E, Donska S, Gonzalez A, Izraeli S, Janic D, Jazbec J, Konja J, Kaiserova E, Kowalczyk J, Kovacs G, Li CK, Magyarosy E, Popa A, Stark B, Jabali Y, Trka J, Hrusak O, Riehm H, Masera G, Schrappe M. Intensive chemotherapy for childhood acute lymphoblastic leukemia: results of the randomized intercontinental trial ALL IC-BFM 2002. J Clin Oncol. 2014 Jan 20;32(3):174-84. doi: 10.1200/JCO.2013.48.6522. Epub 2013 Dec 16.</citation>
    <PMID>24344215</PMID>
  </results_reference>
  <results_reference>
    <citation>Lymphoma Study Group, Subspecialty Group of Hematology, the Society of Pediatrics, Chinese Medical Association; Lymphoma Study Group Committee of Pediatrics Chinese Anti-Cancer Association. [A collaborative study of children with lymphoblastic non-Hodgkin's lymphoma in China]. Zhonghua Er Ke Za Zhi. 2015 Dec;53(12):931-7. Chinese.</citation>
    <PMID>26887549</PMID>
  </results_reference>
  <results_reference>
    <citation>Burkhardt B, Woessmann W, Zimmermann M, Kontny U, Vormoor J, Doerffel W, Mann G, Henze G, Niggli F, Ludwig WD, Janssen D, Riehm H, Schrappe M, Reiter A. Impact of cranial radiotherapy on central nervous system prophylaxis in children and adolescents with central nervous system-negative stage III or IV lymphoblastic lymphoma. J Clin Oncol. 2006 Jan 20;24(3):491-9.</citation>
    <PMID>16421426</PMID>
  </results_reference>
  <results_reference>
    <citation>Widjajanto PH, Sumadiono S, Purwanto I, Sutaryo S, Veerman AJ. L-asparaginase: long-term results of a randomized trial of the effect of additional 3 doses during consolidation treatment in the Indonesian WK-ALL-2000 protocol. J Pediatr Hematol Oncol. 2013 Nov;35(8):597-602. doi: 10.1097/MPH.0b013e31827e7f89.</citation>
    <PMID>23389497</PMID>
  </results_reference>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 24, 2016</study_first_submitted>
  <study_first_submitted_qc>July 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 27, 2016</study_first_posted>
  <last_update_submitted>December 10, 2017</last_update_submitted>
  <last_update_submitted_qc>December 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Isophosphamide mustard</mesh_term>
    <mesh_term>Pegaspargase</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
    <mesh_term>Daunorubicin</mesh_term>
    <mesh_term>Asparaginase</mesh_term>
    <mesh_term>6-Mercaptopurine</mesh_term>
    <mesh_term>Vindesine</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

